Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

NCT03594682 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT03594682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03594682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study
Lead sponsor
Beijing Chest Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 31, 2018
Completion date
July 31, 2020
Enrollment
31 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iiib, nsclc stage iv